Magnetoencephalography / Magnetic Resonance Spectroscopy Dose Response Study of Arbaclofen in Autism Spectrum Disorder

Trial Profile

Magnetoencephalography / Magnetic Resonance Spectroscopy Dose Response Study of Arbaclofen in Autism Spectrum Disorder

Recruiting
Phase of Trial: Phase 0

Latest Information Update: 18 Aug 2017

At a glance

  • Drugs Arbaclofen (Primary)
  • Indications Autistic disorder; Pervasive child development disorders
  • Focus Therapeutic Use
  • Most Recent Events

    • 14 Aug 2017 Planned number of patients changed from 20 to 40.
    • 14 Aug 2017 Planned End Date changed from 1 Jun 2018 to 1 Aug 2019.
    • 14 Aug 2017 Planned primary completion date changed from 1 Oct 2017 to 1 Aug 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top